Valuation: Grace Therapeutics, Inc.

Market Cap 55.72M 39.59M 35.29M 32.71M 29.63M 3.75B 56.52M 392M 154M 1.97B 149M 146M 6.27B P/E 2027 *
-1.59x
P/E 2028 * -4.14x
Enterprise Value 55.72M 39.59M 35.29M 32.71M 29.63M 3.75B 56.52M 392M 154M 1.97B 149M 146M 6.27B EV / Sales 2027 *
-
EV / Sales 2028 * 8.14x
Free-Float
81.32%
Yield 2027 *
-
Yield 2028 * -
1 day+5.32%
1 week-1.98%
Current month-7.91%
1 month-6.16%
3 months-19.84%
6 months-56.96%
Current year-42.77%
1 week 1.82
Extreme 1.8216
2.07
1 month 1.82
Extreme 1.8216
2.18
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.75
Extreme 1.75
5.18
5 years 1.72
Extreme 1.72
11.26
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 04/04/2023
Director of Finance/CFO 55 05/01/2024
Chief Tech/Sci/R&D Officer 65 08/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 04/04/2023
Director/Board Member 59 10/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/26
Opaleye Management, Inc.
BuyCompany 36,347 0.1728%
12/10/26
Opaleye Management, Inc.
BuyCompany 7,215 0.0343%
05/10/26
Opaleye Management, Inc.
BuyCompany 1,694 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
+5.32%-1.98%-36.54%-20.48% 39.55M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +3.33%-0.45%+43.96%+106.92% 37.58B
Weighted average by Cap. +3.05%+0.62%+51.68%+122.70%

Financials

2027 *2028 *
Net sales - 6.84M 4.86M 4.33M 4.02M 3.64M 461M 6.94M 48.13M 18.86M 241M 18.25M 17.87M 770M
Net income -34.73M -24.68M -22M -20.39M -18.47M -2.34B -35.23M -244M -95.75M -1.23B -92.65M -90.72M -3.91B -16.92M -12.02M -10.71M -9.93M -9M -1.14B -17.16M -119M -46.64M -597M -45.13M -44.19M -1.9B
Net Debt - -
Projected Income Statement - Annual - Grace Therapeutics, Inc.
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
20/10/26 $1.960 +4.26% 94,370
19/10/26 $1.880 -0.53% 90,431
16/10/26 $1.890 -3.08% 168,796
15/10/26 $1.950 +3.17% 109,289
14/10/26 $1.890 -5.03% 177,972
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Grace Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.754CAD
Average target price
8.342CAD
Spread / Average Target
+202.95%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Grace Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. GRCE Stock